Regenerative medicine giant Organogenesis Holdings Inc (ORGO) recently announced the successful completion of a key meeting with the U.S. Food and Drug Administration (FDA).

The two parties reached a consensus on the clinical development pathway of Renu® regenerative cell technology for the treatment of knee osteoarthritis pain. The company clearly stated that it will accelerate the regulatory submission process based on the meeting's guidance and plans to officially submit a Biologics License Application (BLA). This innovative therapy aims to target and repair knee cartilage tissue through a cell regeneration mechanism, providing a new non-surgical intervention option for hundreds of millions of osteoarthritis patients worldwide. This milestone event marks a significant breakthrough in the commercialization process of the Renu® product. Industry analysts pointed out that if approved for market launch, this product could reshape the market landscape of the orthopedic pain treatment sector. Influenced by this positive news, the company’s stock price showed an upward trend in after-hours trading.